Batefenterol

Star0

DB12526InvestigationalSmall molecule

Batefenterol has been used in trials studying the treatment of Pulmonary Disease, Chronic Obstructive.

Mechanism: Pharmacologically active on Muscarinic acetylcholine receptor M3, Muscarinic acetylcholine receptor M2, and Beta-2 adrenergic receptor
Curator reviewed
Formula / weight: C₄₀H₄₂ClN₅O₇ · 740.25 g/mol (avg)
Code names: GSK-961081A

Resolves to

Compound

UNII1IAT42T80TCAS743461-65-6ChEMBLCHEMBL3039518PubChem10372836

Structure

InChIKeyURWYQGVSPQJGGB-DHUJRADRSA-NSMILESCOC1=CC(NC(=O)CCN2CCC(CC2)OC(=O)NC2=CC=CC=C2C2=CC=CC=C2)=C(Cl)C=C1CNC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1

Targets

P20309CHRM3P08172CHRM2P07550ADRB2

What you can answer from here — as of September 13, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

671Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with Batefenterol, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account